Fourth Quarter 2007 Revenue Increases 32% to $14.2 Million
Gross Profit Margin at 58.2% Sets Quarterly Record
MINNEAPOLIS, Feb. 25 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported financial results for the fourth quarter and full year ended December 31, 2007. Revenue for the quarter was $14.2 million, up 32.4% from $10.7 million reported in the fourth quarter of 2006.
Contributing to the strong fourth quarter revenue growth was a 166.7% increase in revenues from the Company's ATS CryoMaze(TM) cryoablation products for the treatment of cardiac arrhythmias. Revenue from this product line rose to $3.6 million. Revenue from the Company's heart valve therapy products, consisting of mechanical valves, tissue valves and repair products, was up 13.3% on a year-over-year basis to $10.3 million. The growth reflected a 13.5% increase in mechanical valve revenue. Revenue from products and services other than the Company's mechanical valves represented 33% of total revenue during the fourth quarter of 2007 compared with 21% in the fourth quarter of 2006.
Gross profit margin for the fourth quarter of 2007 set another quarterly record of 58.2% compared with 51.0% for the fourth quarter of 2006, and 56.3% for the third quarter of 2007. The prior record gross margin was 57.8% in the first quarter of 2007.
"Our strong fourth quarter revenue growth and improved gross profit demonstrate continuing progress towards our goal of leadership in cardiac surger (909)
Net proceeds from sales of common stock
and warrants 31,196 123
Other 168 -
Net cash provided by financing activities 37,637 714
Other items (203) 544
Increase (decrease) in cash and
cash equivalents $5,868 ($12,008)
ATS Medical, Inc.
Selected Revenue Information
Revenue for the Three Months Revenue for the Year
Ended December 31, Ended December 31,
2007 2006 2007 2006
Heart valve therapy $10,336 $9,122 $38,558 $35,343
Surgical arrhythmias 3,576 1,341 9,689 4,554
Surgical tools &
accessories 305 277 1,340 552
Total revenue $14,217 $10,740 $49,587 $40,449y by advancing the standards in the treatment of heart valve disease and cardiac arrhythmias," said Michael Dale, Chairman, President and Chief Executive Officer. "We have made substantial progress in diversifying our cardiac surgery offerings, while continuing to grow our mechanical heart valve franchise. We are particularly pleased by the increased revenue contribution of our new product lines designed to treat atrial fibrillation and heart valve repair therapies."
Recent and Upcoming New Product Highlights
-- Dr. James Cox -- Effective January 1, 2008, Dr. Cox joined ATS Medical
as Medical Director. Dr. Cox is a world renowned cardiac surgeon and
is regarded as a leading expert in the treatment of atrial
fibrillation. During his illustrious career he developed the original
cut-and-sew Maze procedure. The original Maze procedure is considered
the 'Gold Standard' solution for clinical success in the treatment of
atrial fibrillation due to the >90% freedom from atrial fibrillation
at fifteen years of follow-up. Dr. Cox is leading ATS in the quest to
bring the long-term clinical success of his Maze procedure to a
minimally invasive approach through the development of new tools and
clinical techniques that leverage the ATS CryoMaze technology.
-- ATS CryoMaze surgical ablation probes and clamps -- Several new
products are under development to enhance the utility of the Company's
existing products and tools for the treatment of atrial fibrillation.
The Company anticipates launching a next generation ablation clamp and
probe in mid 2008.
-- Stand Alone Atrial Fibrillation -- Over fifteen US centers have
performed stand-alone ablation using the existing ATS CryoMaze
products. These efforts include a study at East Carolina University
where 57 patients have been treated for atrial fibrillation using ATS
CryoMaze through minimally invasive access. The results of the study
demonstrate over 90% freedom from atrial fibrillation at six months.
Tissue Heart Valves
-- ATS 3f(R) Aortic Bioprosthesis: The Company's first generation tissue
valve has been approved for sale in Europe and Canada and launch
activities in these geographies are underway. The ATS 3f Aortic
Bioprosthesis represents the Company's first product targeted at the
largest market in cardiac surgery, tissue heart valves.
As announced previously, the Food and Drug Administration (FDA) has
asked ATS to provide additional information and clarification in
support of its PMA for the ATS 3f Aortic Bioprosthesis. The request
relates primarily to in-vitro testing submitted in the original IDE
application. The Company intends to work collaboratively with the FDA
to answer all questions early in 2008. Management remains confident
that the ATS 3f Aortic Bioprosthesis has met or exceeded all of the
requirements and is approvable, but it is now anticipated in the
second half of 2008.
-- ATS 3f Enable(TM) Aortic Bioprosthesis: Enrollment in the Company's
European clinical trial of its Enable tissue valve designed to provide
a less invasive approach for aortic valve replacement continues to
progress with excellent clinical results. The Company expects to
reach enrollment of 100 patients in the pivotal stage of the trial
around mid year, and anticipates its first regulatory approval for
commercialization in 2009.
-- ATS Open Pivot AP360(TM) Mechanical Heart Valve: The Company received
FDA approval of its ATS AP360 Heart Valve in December 2007. The AP360
is the Company's most competitive Open Pivot product, with the same
hemodynamic features as its existing supra annular AP valve but with a
revised cuff design to enable easier suturing. A limited launch has
begun and initial physician experience has been extremely positive.
The Company is currently building inventory in preparation for a wider
launch in the second quarter.
-- ATS Simulus(R) Semi-Rigid and Adjustable Flexible Rings: Initial
launch and implants have been completed and surgeon feedback has been
very positive. Both rings have been designed to be easily used with
the da Vinci(R) robotic system from Intuitive Surgical (Traded on the
NASDAQ stock exchange under the symbol "ISRG") and minimally invasive
repair techniques. Because of the ease of suture placement, the ATS
Simulus Flexible rings and bands are fast becoming the annuloplasty
device of choice among surgeons performing surgical robotic mitral
"We finished 2007 with good momentum and a strong product pipeline that will continue to drive our growth in 2008," continued Mr. Dale. "Our new development efforts have produced innovative new products designed specifically to improve efficacy for the cardiac surgeon and safety for their patients. As a result, we have made substantial progress on several key milestones -- diversifying our revenue sources, leveraging our sales force and enhancing our profit potential. We believe 2008 will be another landmark year for ATS and we look forward to continued growth and enhanced financial performance."
Additional Financial Results
The operating loss for the fourth quarter was $4.9 million compared with an operating loss of $5.6 million in the fourth quarter of 2006. The net loss for the 2007 fourth quarter was $6.2 million, or $0.10 per share, compared with $6.1 million, or $0.15 per share in the fourth quarter of 2006.
Full Year 2007 Results
For the full year 2007, revenue totaled $49.6 million, 22.6% above 2006 revenue of $40.4 million. The Company reported a net loss for 2007 of $23.0 million, or $0.44 per share, compared to a net loss of $27.7 million, or $0.83 per share, in 2006. The net loss for 2007 included charges for acquired in-process research and development of $3.5 million related to the CryoCath asset acquisition and $0.8 million related to discontinuance of the PARSUS development program. The net loss for 2006 included a charge for acquired in-process research and development of $14.4 million related to the acquisition of 3f Therapeutics.
For the full year 2008 the Company expects revenue to grow approximately 21% to 29% from 2007 to a range of $60 to $64 million. The Company continues to expect to generate a profit in the fourth quarter of 2008.
Conference Call Today
ATS management will host a conference call today, February 25, 2008 at 5:00 p.m. ET to discuss its fourth quarter financial results and current corporate developments. The dial-in number for the conference call is 800-218-4007 for domestic participants and 303-262-2142 for international participants. A live webcast of the call can also be accessed at http://www.atsmedical.com by clicking on the Investors icon.
A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will remain available for seven days. The replay can be accessed by dialing 800-405-2236 for domestic participants and 303-590-3000 for international callers, using the passcode 11109130#.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, is headquartered in Minneapolis, Minnesota. More than 145,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3f(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(R) annuloplasty products for heart valve repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company
and its management. Actual results could differ materially from those
projected in the forward looking statements as a result of a number of
important factors, including the results of clinical trials, the timing of
regulatory approvals, the integration of 3f Therapeutics and the surgical
cryoablation business of CryoCath Technologies, Inc., regulatory actions,
competition, pricing pressures, supplier actions and management of growth.
For a discussion of these and other risks and uncertainties that could
affect the Company's activities and results, please refer to the Company's
filings with the Securities and Exchange Commission, including its Form
10-K for the year ended December 31, 2006 and its most recent quarterly
report on Form 10-Q.
ATS Medical, Inc.
Condensed Consolidated Statements of Operations
(in thousands except per share amounts)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
Net sales $14,217 $10,740 $49,587 $40,449
Cost of goods sold 5,937 5,266 21,348 19,568
Gross profit 8,280 5,474 28,239 20,881
Sales and marketing 7,019 5,851 24,633 21,008
development 2,173 2,011 7,546 3,381
and development - - 3,500 14,400
termination expense - 657 - 733
administrative 3,099 2,498 10,417 8,786
intangibles 885 106 2,516 106
impairment - - 755 -
expenses 13,176 11,123 49,367 48,414
Operating loss (4,896) (5,649) (21,128) (27,533)
Interest expense, net (555) (434) (1,822) (1,669)
(expense) (594) 3 61 1,528
Net loss before
income taxes (6,045) (6,080) (22,889) (27,674)
Income tax expense 116 - 119 -
Net loss ($6,161) ($6,080) ($23,008) ($27,674)
Net loss per share:
Basic and diluted ($0.10) ($0.15) ($0.44) ($0.83)
number of shares
Basic and diluted 59,412 40,304 52,589 33,537
ATS Medical, Inc.
Condensed Consolidated Balance Sheets
December 31, December 31,
Cash and short-term investments $14,669 $10,704
Accounts receivable 11,186 11,677
Inventories 18,743 18,782
Prepaid expenses 1,143 1,175
Total current assets 45,741 42,338
Property and equipment, net 7,739 8,213
Intangible assets 50,779 33,155
Other assets 1,638 2,134
Total assets $105,897 $85,840
Liabilities & shareholders' equity
Accounts payable $4,794 $3,183
Accrued compensation 2,361 2,589
Other accrued liabilities 2,000 2,457
Current maturities of bank notes payable 2,457 1,133
Warrant liability 3,913 -
Total current liabilities 15,525 9,362
Convertible senior notes payable 17,436 17,394
Bank notes payable 6,143 1,194
Payable to CryoCath Technologies Inc. 1,742 -
Deferred income taxes 95 -
Shareholders' equity 64,956 57,890
Total liabilities & shareholders' equity $105,897 $85,840
ATS Medical, Inc.
Consolidated Condensed Statements of Cash Flow
Year Ended December 31,
Net loss ($23,008) ($27,674)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 4,622 1,924
Loss on disposal of equipment - 26
Stock compensation expense 1,454 1,103
Acquired in-process research and development 3,500 14,400
Impairment of intangibles 755 -
Deferred income taxes 95 -
Non-cash interest expense 546 463
Change in value of common stock appreciation
rights and convertible senior notes
derivative liabilities 554 (1,528)
Changes in operating assets and liabilities 1,939 1,456
Net cash used in operating activities (9,543) (9,830)
Maturities (purchases) of short-term
investments, net 1,903 (990)
Acquisition of assets of CryoCath
Technologies Inc. (21,074) -
Business acquisition costs,
net of cash acquired (1,791) (717)
Payments for technology licenses
and other intangibles (277) (521)
Purchases of furniture, machinery
and equipment (748) (1,208)
Other (36) -
Net cash used in investing activities (22,023) (3,436)
Advances on bank notes payable 8,600 1,500
Repayments on bank notes payable (2,327)
|SOURCE ATS Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved